Alpha Cognition Inc. (ACOGF)
| Previous Close | 0.4000 |
| Open | 0.3950 |
| Bid | 0.3950 x 0 |
| Ask | 0.4149 x 312500 |
| Day's Range | 0.3950 - 0.3950 |
| 52 Week Range | 0.1638 - 0.7398 |
| Volume | |
| Avg. Volume | 148,822 |
| Market Cap | 60.974M |
| Beta (5Y Monthly) | 3.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireAlpha Cognition Announces Change of Officer
VANCOUVER, British Columbia, October 03, 2024--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Don Kalkofen has resigned as the Chief Financial Officer of the Company to pursue other opportunities.
Business WireAlpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
VANCOUVER, British Columbia, September 24, 2024--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the closing of a $4.545 million bridge financing through the offer of convertible notes and warrants.
Business WireAlpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
VANCOUVER, British Columbia, August 19, 2024--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 18/463,157, entitled "Solid Forms of ALPHA-1062 Gluconate," which includes claims covering an additional novel crystallin
